Navalign LLC Buys 232 Shares of CVS Health Co. (NYSE:CVS)

Navalign LLC grew its stake in shares of CVS Health Co. (NYSE:CVS) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,353 shares of the pharmacy operator’s stock after buying an additional 232 shares during the period. Navalign LLC’s holdings in CVS Health were worth $896,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CVS. Bryn Mawr Capital Management LLC boosted its position in shares of CVS Health by 74.0% during the third quarter. Bryn Mawr Capital Management LLC now owns 43,213 shares of the pharmacy operator’s stock worth $3,017,000 after acquiring an additional 18,385 shares during the last quarter. Value Partners Investments Inc. increased its holdings in shares of CVS Health by 26.5% in the third quarter. Value Partners Investments Inc. now owns 991,601 shares of the pharmacy operator’s stock worth $69,261,000 after purchasing an additional 207,702 shares during the last quarter. Sonora Investment Management Group LLC lifted its position in shares of CVS Health by 1.6% in the third quarter. Sonora Investment Management Group LLC now owns 50,488 shares of the pharmacy operator’s stock worth $3,525,000 after buying an additional 774 shares in the last quarter. Checchi Capital Advisers LLC grew its holdings in CVS Health by 2.3% during the 3rd quarter. Checchi Capital Advisers LLC now owns 10,405 shares of the pharmacy operator’s stock valued at $726,000 after buying an additional 233 shares in the last quarter. Finally, Personal CFO Solutions LLC raised its holdings in shares of CVS Health by 2.6% during the 3rd quarter. Personal CFO Solutions LLC now owns 19,355 shares of the pharmacy operator’s stock worth $1,351,000 after acquiring an additional 491 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Price Performance

CVS traded up $0.33 during trading on Thursday, hitting $79.76. The company’s stock had a trading volume of 8,872,358 shares, compared to its average volume of 11,297,311. The company has a current ratio of 0.86, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $100.37 billion, a price-to-earnings ratio of 12.37, a P/E/G ratio of 1.05 and a beta of 0.51. The business’s fifty day simple moving average is $75.66 and its 200 day simple moving average is $73.46. CVS Health Co. has a twelve month low of $64.41 and a twelve month high of $83.25.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. The company had revenue of $93.81 billion during the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.99 earnings per share. On average, equities research analysts forecast that CVS Health Co. will post 8.33 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a yield of 3.34%. CVS Health’s payout ratio is presently 41.18%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CVS. Cantor Fitzgerald restated an “overweight” rating and issued a $87.00 target price on shares of CVS Health in a report on Thursday, February 8th. StockNews.com downgraded CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. HSBC assumed coverage on shares of CVS Health in a research report on Friday, December 22nd. They issued a “buy” rating and a $94.00 price objective on the stock. TD Cowen dropped their price objective on CVS Health from $102.00 to $99.00 and set an “outperform” rating for the company in a report on Monday, December 11th. Finally, Barclays assumed coverage on shares of CVS Health in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.21.

Insiders Place Their Bets

In other news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the transaction, the executive vice president now owns 39,765 shares in the company, valued at approximately $3,059,916.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.25% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.